Biocon is currently trading at Rs. 276.35, up by 5.75 points or 2.12% from its previous closing of Rs. 270.60 on the BSE.
The scrip opened at Rs. 280.00 and has touched a high and low of Rs. 285.40 and Rs. 274.55 respectively. So far 91051 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 323.30 on 24-Feb-2020 and a 52 week low of Rs. 211.30 on 20-Aug-2019.
Last one week high and low of the scrip stood at Rs. 290.50 and Rs. 268.20 respectively. The current market cap of the company is Rs. 33150.00 crore.
The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 21.64% and 17.70% respectively.
Biocon subsidiary -- Biocon Sdn Bhd has received the Establishment Inspection Report (EIR) from the USFDA for the Pre-Approval Inspection (PAI) of its Insulins manufacturing facility in Malaysia, for Insulin Glargine. The inspection was conducted between February 10 and February 21, 2020.
The Inspection has been closed with a ‘VAI’ (Voluntary Action Indicated) classification in the EIR, for the three observations issued at the conclusion of the inspection in Feb 2020.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.